ASCEND-4, 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of ceritinib versus chemotherapy in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC


NCT01828099    Lancet 2017 Jan 23;:  

Studied treatment oral ceritinib 750 mg/day
Control treatment platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed

Patients untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC
Group sizes-9 / -9

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design

EndpointX1N1X0N0TE95% CI OS - -9 - -9 no data PFS - -9 - -9 no data0,22,01,0

Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017 Jan 23;:     [PMID: 28126333]   link to pdf   add to Mendeley record NCT01828099

Registering number NCT01828099 (see trial on
Code Name


Appears in following systematic reviews: